ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

2024-09-05T08:00:00Z
  • New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities

MELBOURNE, Australia, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, has been awarded an additional US $3.18 million contract from the U.S. Department of Defense (DOD).

The new funding extends the US $8.18 million already committed by the DOD to support the development of INNA-051. It will be used to expand ENA’s Phase Ib study of its dry powder formulation of INNA-051 to younger adults and support product optimization ahead of Phase IIb initiation.

The IND opening Phase Ib study in adults over the age of 60 was initiated in Q2 2024. A DOD-funded protocol amendment will support inclusion of individuals aged 18-45 with the aim of informing dose selection for subsequent trials. Results from the study are expected in the Q4 2024.

ENA Respiratory’s CEO, Christophe Demaison, PhD said: “This new funding from the DOD is further recognition of the potential of INNA-051 to play a significant role in protecting individuals at risk of serious harm from respiratory viral infections, including those with occupational risk. We are grateful to the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for its continued support.”

The contract was awarded by the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), in collaboration with the Defense Innovation Unit (DIU). Reference to the DOD, JPEO-CBRND, or other agency of the United States does not constitute or imply an endorsement or recommendation by the U.S. government or any agency thereof.

About ENA Respiratory

ENA Respiratory is a clinical-stage pharmaceutical company tackling serious respiratory viral infections through the development of host defence immune modulators which locally prime and boost the body’s innate immune response – the natural first line of defence. Being virus-agnostic, immune modulators are complementary to often virus-specific vaccines and existing direct-acting antivirals.

The company’s lead product, INNA-051, is a potent agonist of toll-like receptor 2/6 (TLR2/6) which plays a key role in recognising pathogens and triggering the innate immune response. With a safe profile supporting prophylaxis use, it has demonstrated accelerated virus clearance and stimulation of antiviral host defences, including IFN Type I & III responses, in a Phase IIa proof-of-principle study using a human influenza-challenge model.

INNA-051 is being developed as a convenient, once-a-week nasal dry powder product to prevent complications associated with respiratory viral infections in at-risk populations, including the elderly, those with an underlying medical condition (including chronic lung conditions, diabetes, kidney disease, and cardiovascular disease) and individuals with occupational risk (e.g. first responders, military or essential services personnel).

Headquartered in Melbourne, Australia, the company has raised US$26M (AU$44million) in equity financing from Brandon Capital, The Minderoo Foundation and Uniseed. It is partnered with the US COPD Foundation to support the clinical development of INNA-051 in COPD and has been awarded a US$11.3 million contract from the U.S. Department of Defence. It is a member of BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate novel potential solutions for future pandemics.

For more information, please visit https://enarespiratory.com
Follow us on LinkedIn: https://www.linkedin.com/company/enarespiratory-pty-ltd/

For further information please contact:
Media – Australia
Kirrily Davis, E: kdavis@bcpvc.com M: +61 (0)401 220228
Media – International
Charles Consultants
Sue Charles, E: sue.charles@charles-consultants.com M: +44 (0)7968 726585
Chris Gardner, E: Chris@CGComms.onmicrosoft.com M: +44 (0)7956 031077


Globe Newswire News

RSS Australian Mining Releases

  • Xanadu’s Near-Term Outlook
    TORONTO , Jan. 21, 2025 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) is pleased to provide an update on The Kharmagtai Project and associated discussions about the next steps for the development of the Kharmagtai copper-gold Project with our JV partner, Zijin Mining Group (Zijin). Highlights Xanadu delivered […]
  • Technical Report to Support Kharmagtai Pre-Feasibility Study
    TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) announces that the Company has filed an independent National Instrument 43-101 technical report titled National Instrument 43-101 Report, Kharmagtai Copper-Gold Project, South Gobi, Mongolia, effective 10 October 2024. The NI 43-101 Technical Report for the Kharmagtai […]
  • Perseus Mining December Quarter Report Webinar
    Perth, Jan. 09, 2025 (GLOBE NEWSWIRE) -- QUARTERLY REPORT INVESTOR WEBINAR / CALL Perth, Western Australia/ January 9, 2025/ Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its December 2024 Quarterly Results, which are anticipated for release around 8:30am AEDT on Wednesday January 29, 2025. CALL DETAILS Australia: […]
  • Completion of Placement to Zijin Mining
    TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce that the placement of 26,515,543 fully paid ordinary shares to Jinping (Singapore) Mining Pte Ltd, a wholly owned indirect subsidiary of Zijin Mining Group Co. Ltd (Zijin), at an issue price of A$0.055 per share, […]
  • Confidence Boosting Infill Drilling at Nyanzaga Project
    Perth, Dec. 05, 2024 (GLOBE NEWSWIRE) -- CONFIDENCE BOOSTING INFILL DRILLING AT NYANZAGA PROJECT Perth, Western Australia/December 5, 2024/ Perseus Mining Limited (ASX/TSX: PRU) is pleased to provide an update on ongoing resource definition drilling being conducted at its recently acquired Nyanzaga Gold Project in Tanzania (Nyanzaga or the Project). Designed to increase Perseus’s understanding […]
  • Perseus Mining General Meeting Results
    Perth, Nov. 25, 2024 (GLOBE NEWSWIRE) -- ANNUAL GENERAL MEETING RESULTS Perseus Mining Limited (ASX/TSX: PRU) (Perseus) wishes to release the results of its Annual General Meeting, held on 22 November 2024 at 3pm AWST. All six resolutions were decided on a poll and passed. In accordance with ASX Listing Rule 3.13.2 and Section 251AA […]
  • High Priority Copper Drill Targets Defined at Sant Tolgoi
    TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) is pleased to announce strong surface copper assay results from its Sant Tolgoi Project located in Zavkhan Province of Western Mongolia (Figures 1 and 2). Geological mapping, surface rock-chip sampling and geophysics have confirmed the preference of […]
  • Funding Expanded to $7.5 million & Section 708A(5)(e) Notice
    Not for release to US wire services or distribution in the United States Highlights 4 November Placement expanded to $7.5 million, an increase of $2.0 million on the same termsIncludes 10 million new shares to a sophisticated Australian investorIncludes 26.5 million new shares to Zijin Mining Group Co., Ltd (Zijin) for $1.46 million to maintain […]
  • Xanadu Mines Completes $5.5 Million Placement
    Not for release to US wire services or distribution in the United States TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) advises that on 8 November 2024, it issued 100,000,004 fully paid ordinary shares at a price of $0.055 per share, to a range of sophisticated investors […]
  • Xanadu Mines Announces $5.5 Million Placement
    Not for release to US wire services or distribution in the United States Highlights Firm commitments received for a Placement to raise approximately $5.5 million (before costs).The Placement was well supported by both domestic and international, natural resources-focused institutional investors.The Placement may be expanded to include other potential strategic parties on similar terms, subject to […]

Stay up to date

Get notified about the latest gold mining news as soon as it happens or choose daily or weekly deliveries.
GET Newsletters
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram